Call or Text Us Today! (614) 427-9296
Call or Text Us Today! (614) 427-9296
Call or Text Us Today! (614) 427-9296
Call or Text Us Today! (614) 427-9296
TB006 stands as a groundbreaking drug designed to address Alzheimer's Disease (AD) by targeting a protein known as Galectin-3 (Gal-3), a key player in brain inflammation linked to the progression of AD. TB006 addresses the complexities of Alzheimer's Disease by disrupting neuroinflammation processes, offering hope for a new era in Alzheimer's Disease therapy. TB006 is a vital breakthrough in neuroscience for Alzheimer's treatment.
Promising results have emerged from pre-clinical studies, demonstrating the efficacy of TB006 in degrading neurotoxic oligomers and blocking or even reversing the progression of AD. Animal model studies have shown a significant reduction in total Abeta plaques and other neurodegeneration biomarkers after just two weeks of treatment with TB006.
In clinical trials, TB006 has demonstrated a superior safety profile, with no reported drug-related adverse events in a nearly completed healthy volunteer trial. Ongoing phase I/II trials for Alzheimer's Disease are anticipated to yield promising efficacy data in Q2/2022. The drug has shown potential in easing and even reversing signs of Alzheimer's disease in patients, with 47% exhibiting signs of disease reversal or cognitive improvement, and 28% showing stabilization.
TB006 works by binding to Gal-3, preventing it from acting as a glue that causes Abeta to aggregate into toxic plaques. By disrupting this process, TB006 dissolves existing plaques, allowing neurons to communicate more effectively. This unique mechanism of action positions TB006 as a revolutionary drug with the potential to halt and reverse the progression of Alzheimer's Disease.
The therapeutic efficacy of TB006 has been underscored by its ability to significantly reduce the aggregation of Aβ/Tau proteins and neuroinflammation in AD in vivo model studies. In a Phase 1b/2a proof-of-concept trial involving mild to severe AD patients, TB006 demonstrated substantial improvements in cognition and functioning. Ongoing Phase 2 trials are currently evaluating its effectiveness in AD patients and those with acute ischemic stroke.
Polaris Rejuvenation
999 Polaris Parkway, Suite 100, Columbus, OH 43240
Call or Text Us Today! (614) 427-9296
Copyright © 2024 Polaris Rejuvenation - All Rights Reserved.